Novel Approaches to the Targeting of GPCRs towards Improved Treatment of Schizophrenia

靶向 GPCR 改善精神分裂症治疗的新方法

• 批准号: nhmrc : 1052304
• 负责人: Dr Jonathan Lane
• 金额: $ 27.69万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Career Development Fellowships
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/novel-approaches-targeting-treatment-schizophrenia/112266
• 关键词: Novel; Approaches; Targeting; GPCRs; towards

The focus of these studies are two important types of brain proteins that have been implicated in various symptoms associated with schizophrenia. The aim is to exploit two emerging paradigms of drug action at these brain proteins that will allow us to target them in a more selective manner. In particular, these studies will provide a starting point for safer, more effective treatments for schizophrenia.

这些研究的重点是两种重要的脑蛋白，它们与精神分裂症的各种症状有关。目的是利用药物对这些大脑蛋白质作用的两种新兴范式，使我们能够以更有选择性的方式靶向它们。特别是，这些研究将为更安全，更有效的精神分裂症治疗提供一个起点。